Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.
Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.